奥曲肽及其类似物用于肿瘤治疗的进展

马寄晓; 叶大铸; 马寄晓; 叶大铸

[1]

Boerman O C, Oyen W J G, Corstens F H M. Between the scylla and charybdis of peptide radionuclide therapy:hitting the tumor and saving the kidney[J]. Eur J Nucl Med, 2001, 28:1447-1449.

[2]

Forssell-Aronsson E, Bernhardt P, Nilsson O, et al. Biodistribution data from 100 patients iv. injected with ¹¹¹In-DTPA-D-pheloctreotide[J]. Acta Oncol, 2004, 43(5):436-442.

[3]

Bushnell D, Menda Y, O'Dorisio T, et al. Effect of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-octreotide (SMT487[Octreo TherTM])treatment[J]. Cancer Biother Radiopharm,2004, 19(1):35-41.

[4]

Pauwels S, Barone R, Walrand S, et al. Practical dosimetry of peptide receptor radionuclide therapy with ⁹⁰Y-labeled somatostatin analogs[J]. J Nucl Med, 2005, 46(1 suppl):92S-98S.

[5]

Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy:Yttrium-90-DOTATOC internal radiotherapy[J]. Am J kidney Dis, 2001,37(4):847-851.

[6]

Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with ⁹⁰Y-DOTATOC in association with amino acid infusion, a phase Ⅰ study[J]. Eur J Nucl Med Mol Imaging, 2003,30(2):207-216.

[7]

Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotidc by a combination of lysine and arginine[J]. Eur J Nucl Med Mol Imaging, 2003, 30(1):9-15.

[8]

Barone R, Pauwels S, De Camps J, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogs[J]. Nephrol Dial Transplant, 2004, 19(9):2275-2281.

[9]

Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with ⁹⁰Y-DOTATOC:relevence of kidney volume and dose rate in finding a dose-effect relationship[J]. J Nucl Med, 2005, 46(lsuppl):99s-106s.

[10]

Gabriel M, Froehlich F, Decristoforo C, et al. EDDA/HYNIC-TOC and ¹⁸F-FDG in thyroid cancer patients with negative ¹³¹I whole body scan[J]. Eur J Nucl Med Mol Imaging, 2004, 31(3):330-341.

[11]

Giammarile F, Houzard C, Bournaud C, et al. Diagnostic management of suspected metastatic thyroid carcinoma:clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine Scans[J]. Eur J Endocrinol, 2004, 150(3):277-283.

[12]

Stokkel M P, Verkooijen R B, Smit J W. Indium-111 octretide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer:diagnostic and prognostic value[J]. EurJ Nucl Med Mol Imaging, 2004, 31(7):950-957.

[13]

Stokkel MP, Rcigman HI, Verkooijen RB, et al. Indiun-111-octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I- 131[J]. J Cancer Res Clin Oncol, 2003, 129(5):287-294.

[14]

Kostoglou-Athanassiou I, Pappas A, Gogou L, et al. Scintigraphy with ¹¹¹In-octreotide and ²⁰¹Tl in a Hurthle cell thyroid carcinoma without detectable radio-iodine uptake. Report of a case and review of the literature[J]. Horm Res, 2003, 60(4):205-208.

[15]

Tounissen J J, Kwekkeboom D J, Kooij P P, et al. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid cancer[J]. J Nucl Med, 2005, 46(1 suppl):107s-114s.

[16]

Rufini V, Salvatori M, Garganese M C, et al. Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma[J]. Rays,2000, 25(2):273-282.

[17]

Papotti M, Kumar U, Volante M, et al. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid[J]. Clin Endocsinol, 2001, 54(5):641-649.

[18]

Bodei L, Haudkiewicz-Junak D, Grana C, et al. Receptor radionuclide therapy with ⁹⁰Y-DOTATOC in patients with medullary thyroid carcinomas[J]. Cancer Biother Radiophasm, 2004, 19(1):65-71.

[19]

Behe M, Behr T M. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies[J]. Biopolymers, 2002, 66(6):399-418.

[20]

Vainas I, Koussis CH, Pazaitou-Panayiotou K, et al. Somatastatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medulary thyroid carcinoma[J]. J Exp Clin Cancer Res, 2004, 23(4):549-559.

[21]

Saga T, Tamaki N, Itoi K, et al. Phase Ⅲ additional clinical study of ¹¹¹In-pentetrootide (MP-1727):diagnosis of gastrointestinal hormone producing tumors based on the presence of somatostatin receptor[J].Kaku Iguku, 2003, 40(2):185-203.

[22]

Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment[J]. Neuroendocrinology, 2004, 80(suppl 1):51-56.

[23]

Gibril F, Jensen R T. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroentero-pancreatic endocrine tumors[J].Dig Liver Dis, 2004, 36(suppl 1):S106-S120.

[24]

Virgolini I, Traub T, Novotny C, et al. Experience with indium-111and yttrium-90-1abeled somatostat in analogs[J]. Curr Pharm Des,2002, 8(20):1781-1807.

[25]

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs[J]. J Nucl Med, 2005, 46:62S-66S.

[26]

Mundschenk J, Unger N, Schulz S, et al. Somatostatin receptor subtypes in human pheochromocytoma:subeellular expression pattern and functional relevance for octrootide scintigraphy[J]. J Clin Endocrin Metab, 2003, 88(11):5150-5157.

[27]

Pless M, Waldherr C, Maecke H, et al. Targeted radiotherapy for small cell lung cancer using ⁹⁰Yttrium-DOTATOC, an Yttrium labelled somatostatin analogue:a pilot trial[J]. Lung Cancer, 2004,45(3):365-371.

[28]

Schmitt A, Bernhardt P, Nilsson O, et al. Radiation therapy of small cell lung cancer with ¹⁷⁷Lu-DOTA-Tyr3-octreotate in an animal model[J]. J Nucl Med, 2004, 45(9):1542-1548.

[29]

Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin[J]. Clin Nucl Med, 2002, 27(1):11-17.

[30]

Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate[J]. J Nucl Med, 2005, 46(Suppl 1):83S-91S.

[31]

Waldherr C, Pless M, Maecke H.R, et al. Tumor response and clinical benefit in neuroendocrin tumors after 7.4Bq ⁹⁰Y-DOTATOC[J]. J Nucl Med, 2002, 43(5):610-616.

[32]

Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic(GEP) tumours with the novel radiolabelled somatostatin analogue[¹⁷⁷Lu-DOTA(0),Tyrs]octreotate[J]. Eur J Nucl Med Mol Imaging, 2003, 30(3):417-422.

[33]

de Jong M, Breeman WA, Valkema R, et al. Combination radionuelide therapy using ¹⁷⁷Lu- and ⁹⁰Y-labeled somatostatin analogs[J]. J Nucl Med, 2005, 46(1 suppl):13S-17S.

[34]

Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future[J]. J Nucl Med, 2005, 46(1 suppl):67S-75S.

[35]

Gotthardt M, Boermann OC, BehrTM, et al. Development and clinical application of peptide-based radiopharmaceuticals[J]. Curr Pharm Des, 2004, 10(24):2951-2963.